Harmonization Guidelines Research Articles

Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT

Heterogeneous approaches exist in regard to the management of disease-related co-morbidities in potential allogeneic haematopoietic cell transplantation (allo-HCT) candidates with myelofibrosis (MF). The EBMT Chronic Malignancies Working Party launched an electronic survey to evaluate how MF-specific comorbidities are approached and whether they ultimately affect the decision to transplant. A total of 41/63 (65%) Centers, all of whom were experienced in the management of MF allo-HCT, responded. Responses were aggregated and reported in a comparative fashion. Screening for portal hypertension (PH) was routinely performed in 54% centers, never in 12% and guided by clinical manifestations in the remaining. Involvement of hepatologists/gastroenterologists was always/very often considered in patients with signs of PH prior to transplant. Centers reported that radiological evidence of PH did not routinely represent a formal contraindication for allo-HCT in most cases (78%). Of note, most centers (61%) did not perform routine screening for gastroesophageal varices; this was systematically considered or guided by clinical manifestations in only 7% and 32% centers, respectively. Presence of gastroesophageal varices was always (15%) or occasionally (19%) considered a formal contraindication to allo-HCT. A prior history of portal vein thrombosis never (78%) or occasionally (15%) represented a formal contraindication. Three Centers would not proceed to transplant in such cases. Less importance was assigned to non-portal splanchnic vein thrombosis (SVT), with all but one centre proceeding to transplant regardless of prior SVT. This survey highlights a considerable heterogeneity across responding centers in approaching MF-related comorbidities prior to transplant, suggesting that harmonisation guidelines are needed to address these issues in this patient population.

HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey.

This survey was conducted to describe current European postnatal prophylaxis (PNP) and infant feeding policies with the aim of informing future harmonized guidelines. A total of 32 senior clinicians with relevant expertise, working in 20 countries within the European Region, were invited to complete a REDCap questionnaire between July and September 2023. Twenty-three of the 32 invited paediatricians responded, representing 16/20 countries. There were multiple respondents from the same country for Italy (n = 5), the UK (n = 2), Germany (n = 2) and France (n = 2). All countries use risk stratification to guide PNP regimen selection. Nine out of 16 countries reported three risk categories, six out of 16 reported two, and one country reported differences in categorization. Criteria used to stratify risk varied between and within countries. For the lowest risk category, the PNP regimen reported ranged from no PNP to up to four weeks of one drug; the drug of choice reported was zidovudine, apart from one country which reported nevirapine. For the highest risk category, the most common regimen was zidovudine/lamivudine/nevirapine (20/23 respondents); regimen duration varied from twoto six weeks with variation in recommended dosing. Guidelines support breastfeeding for infants born to people living with HIV in eight out of 16 countries; in the other eight, guidelines do not support/specify. Guidelines and practice for PNP and infant feeding vary substantially across Europe and within some countries, reflecting the lack of robust evidence. Effort is needed to align policies and practice to reflect up-to-date knowledge to ensure the vertical transmission risk is minimized and unnecessary infant HIV testing and PNP avoided, while simultaneously supporting families to make informed decisions on infant feeding choice.

Method Development and Validation of Luliconazole Bulk Drug Using Reverse Phase - HPLC Technique

Objective: To develop and validate the RP- HPLC method for determining Luliconazole in bulk and pharmaceutical formulations. Methods: Following the International Conference on Harmonization (ICH) guidelines, a sensitive, accurate, and specific reversed-phase HPLC technique was created and validated for the detection of Luliconazole. Using high-performance liquid chromatography, this drug was examined. A better separation of the drug was achieved by using Agilent Eclipse XDB C (4.6mm x 250mm, 5µm) with a mobile phase consisting of a mixture of Acetonitrile and Buffer in HPLC water. The ratio of 30:70 v/v (Formic acid and Acetonitrile) at a flow rate of 1.0 ml/ min and the detection was at the wavelength 295 nm using a Photodiode Arrays Detector. The planned method was able to produce good quality separation of the drug and its degradation products with sharp peaks. Findings: Luliconazole had a retention time of 2.38 ± 0.127 minutes. The technique was linear in the range of 10-100 µg/ml, with a correlation (r2) of 0.9995 and a run duration of 4 minutes. The method limit of detection (LOD) and limit of quantification (LOQ) were set at 0.1 and 1 g/ml, respectively. The method accuracy and system precision were estimated, and the findings were calculated as percentage RSD values, which were found to be limitations. Luliconazole recovery was 100% confirming the method's efficiency. Novelty: The presented approach was innovative and successfully fulfilled all validation requirements, including linearity, robustness, accuracy, reduced retention, and run time. This suggests that the method is appropriate for identifying the stability of luliconazole in bulk and pharmaceutical formulations. Keywords: RP-HPLC, Transferosome, ICH guidelines, Validation, Luliconazole

Head Space GC-MS/MS Method for Quantification of Five Nitrosoamine-Genotoxic Impurities in Metformin HCl

Background: N-nitrosamines have recently been discovered in metformin hydrochloride and other generic drugs. To quantify the five N-nitrosamines in metformin hydrochloride, we devised sensitive and reliable multiple reactions monitoring mode-based GCMS/ MS technique, particularly, N-nitrosodiethy amine (NDEA), N-nitroso ethyl isopropylamine (NEIPA), N-nitrosodiisopropylamine (NDIPA), N-nitrosodipropylamine (NDPA), as well as N-nitrosodibutylamine (NDBA). Objective: To develop a sensitive, precise, and accurate MRM mode based GC-MS/MS method for the quantification of five N-nitrosamines in metformin hydrochloride and valídate as per ICH guidelines. Methods: The settings for mass spectrometry and gas chromatography were optimized. With the linearity, sensitivity, specificity, accuracy, and precision of the parameter, the procedure was as per the recommendation of ICH: International Council for Harmonization guidelines. Results: N-nitrosamines in metformin hydrochloride had detection and quantification limits of 0.001 ppm and 0.004 ppm, correspondingly. The obtained results were within the sensitivity limitations issued by the US Food and Drug Administration. The calibration curve's regression coefficients for five N-nitrosamines were over 0.99, demonstrating the process's good linearity. The retrievals of N-nitrosamines in metformin hydrochloride between 97.1 – 127.4 %. The RSD (Relative Standard Deviation) was lower than 10 % for both inter-day and intra-day precision studies. Conclusion: The proposed method exhibited a rapid analysis capability, high accuracy, sensitivity, and precision, making it a trustworthy method for monitoring N-nitrosamines in metformin hydrochloride.

A Method to Determine Metoclopramide Hydrochloride in Oral Dosage Forms by Micellar Liquid Chromatography

Background: Metoclopramide is a widely prescribed antiemetic drug. Its analysis in pharmaceutical formulations often involves procedures using high amounts of toxic chemicals. Objective: A method based on micellar liquid chromatography to determine metoclopramide hydrochloride in several oral dosage forms has been developed. Methods: The drug was resolved from matrix compounds within 6 min using a C18 column with isocratic elution at 1 mL/min utilizing a solution of 0.10 mol/L sodium dodecyl sulfate – 6 % 1- pentanol phosphate buffered at pH 7 as mobile phase, and detection by absorbance at 210 nm. Samples were dissolved or diluted in the mobile phase and directly injected; thus, only one solution had to be prepared for the entire procedure. Besides, it contained mainly harmless chemicals and a minimal amount of organic solvent. Results The procedure was validated by the International Council of Harmonization guidelines and the results were: specificity, calibration range (0.5 – 5.0 mg/L), linearity (r2 > 0.9990), trueness (98.1 – 100.3 %), precision (< 0.7%), robustness, carry-over effect, and system suitability. It was used to analyze commercial samples. Otherwise, it was found the influence of the surfactant on elution strength was nearly three times stronger than that of 1-pentanol. Conclusion: The procedure was reliable, easy-to-conduct, safe, eco-friendly, short-time, widely available and highly sample-throughput, and then useful for routine analysis of metoclopramidebased dosage forms in pharmaceutical quality control.

Establishing a multi-method approach for unprecedented detection and quantification of 13 genotoxic impurities (GTIs) in Apixaban drug substance through ultra-performance liquid chromatography (UPLC).

This groundbreaking study introduces a pioneering development of multi-method approach for the first-ever detection and quantification of 13 genotoxic impurities (GTIs) in Apixaban (Apx) drug substance using ultra-performance liquid chromatography (UPLC) with ultraviolet (UV) detector. In this novel endeavor, two distinct UPLC-UV methods, Method A (for impurities A to G) and Method B (for impurities H to M), were meticulously developed and validated as per International Council for Harmonization (ICH) guidelines to address the challenge of identification and control of 13 GTIs in Apx drug substance. The validation process included rigorous assessment of linearity, accuracy, specificity, precision, limit of quantification (LOQ), and limit of detection (LOD) for each impurity in each method which marks a significant advancement in pharmaceutical analysis. The developed methods address the regulatory requirements set forth by ICH M7(R2) guidelines by providing a reliable approach for quantifying GTIs in Apx drug substance at trace levels to minimize the potential carcinogenic risk to the patients.

Comprehensive analysis of respiratory pharmaceuticals in dietary supplements using advanced chromatographic techniques

Recently, the number of people suffering from respiratory symptoms has continued to increase because of COVID-19 and particulate contamination. Accordingly, the demand for respiratory-related dietary supplements is increasing. Over the past few years, dietary supplements adulterated with pharmaceutical drugs have continued to appear, increasing the risk of side effects; thus, preventive measures are needed. In this study, we developed a simultaneous analysis method for 11 respiratory-related pharmaceutical compounds using ultra-performance liquid chromatography with a photodiode array (UPLC-PDA). The sample preparation method was optimized by comparing filtration and two clean-up methods (QuEChERS), for solid and liquid formulations, and the optimal analytical conditions were established by comparing various analysis parameters. Concerning method validation, all parameters meet International Council for Harmonisation guidelines. Subsequently, 54 types of dietary supplements promoting relief of respiratory-related symptoms were purchased online and analyzed using UPLC-PDA. As a result, theobromine, azelastine, and dexamethasone were detected in three products. In addition, the detected compounds were confirmed by comparing fragmentation patterns using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). This study will contribute to preemptively blocking dietary supplements adulterated with respiratory-related drugs from entering the market and can be used as a reference for future research.

A stability-indicating method development and validation for the determination of related substances in novel synthetic decapeptide by HPLC.

In the present scenario, peptide is an emerging field of research having vast therapeutic applications. Diverse impurities may rise from various stages of the synthesis process and storage of the peptides. Because these contaminants may have an impact on the therapeutic safety and effectiveness of peptides in their approaching applications, they must be identified and carefully monitored. Considering the pharmaceutical importance of the extent of peptides, we were motivated to synthesize a decapeptide and establish a novel gradient reversed-phase high-performance liquid chromatography (RP-HPLC) method for its analysis along with efficient separation of its six related impurities. Different buffers, organic modifiers, and columns were used in the tests for good separation of these impurities. To establish a stability-indicating method, a stress study was also conducted. The International Conference on Harmonization (ICH) guidelines have been followed for validation of the developed analytical method. The validated method revealed sufficient accuracy, specificity, linearity, robustness, precision, and high sensitivity for its intended use. The proposed method could be appropriate for routine analysis and stability assessment of the decapeptide, which might be useful for further scientific investigation.

Validated high performance thin layer chromatographic method for simultaneous quantification of betulinic acid, β-sitosterol and lupeol in fruits, leaves, root bark and stem bark of Dillenia indica Linn

AbstractDillenia indica is one of the important medicinal plants and is extremely popular in many systems of medicine including ayurvedic, homeopathic, and siddha. Traditionally, different parts of this plant have been used to treat cancer, wound healing, diabetes, diarrhea, bone fractures, abdominal pains, cuts and burns. In the present study, a simple, precise, accurate and validated high performance thin layer chromatographic (HPTLC) method was developed for simultaneous estimation of three pharmaceutically active compounds i.e., betulinic acid (BE), β-sitosterol (BT) and lupeol (LP) in fruits, leaves, root bark and stem bark of D. indica. Standards and plant samples were applied on TLC aluminum plate precoated with 0.2 mm layer of silica gel 60F254. The plate was run in a twin glass chamber comprising toluene:methanol:chloroform (8:1:1, v/v/v) as a mobile phase which resulted in better separation of compounds. The plates were immersed in anisaldehyde-sulfuric reagent and then heated at 105 °C for 5 min in CAMAG TLC plate heater for appearance of bands. Densitometric scanning was performed at λmax = 525 nm using tungsten light source in CAMAG TLC Scanner4 armed with WinCATS software. RF values of BE, BT and LP standards and those of plant samples were found to be 0.38 ± 0.01, 0.54 ± 0.01 and 0.65 ± 0.02 respectively. The method was further validated by following the International Conference of Harmonization (ICH) guidelines. For BE, BT and LP, the linear regression data for the calibration plots revealed a satisfactory linear association with correlation coefficients (r2) = 0.9736, 0.9989 and 0.9957, respectively. Linear ranges for BE, BT and LP were 2,000–6,000 ng/band, 200–1,000 ng/band, and 200–600 ng/band respectively. Accuracy of the method was assessed by recovery study conducted at three different levels with the average recovery of 99.19, 99.69 and 100.95% for BE, BT and LP, respectively. The results exhibited the highest content of BE (0.148 ± 0.01%), BT (0.031 ± 0.01%) and LP (0.047 ± 0.01%) in stem bark. The developed method will be useful for routine and quality control analysis of fruits, leaves, root bark and stem bark of D. indica species.

An improved high-resolution method for quantitative separation of empty and filled AAV8 capsids by strong anion exchange HPLC.

Cell and gene therapy (CGT) is a field of therapeutic medicine that aims to treat, prevent, and cure diseases using engineered cells (stem cells, immune cells, and differentiated adult or fetal cells), vectors [Adeno Associated Virus (AAV), Adeno Virus (AV), Herpes Simplex Virus (HSV), Baculo Virus (BV), Lenti Virus (LV), Retro Virus (RV), etc.], and other carriers [non-viral vectors, virus-like particles (VLP), Lipid Nano-Particles (LNP), etc.]. Among viral CGT vectors, adeno-associated viruses and lentiviruses (AAV and LV) are the most widely applied vector platforms. The presence of non-functional (empty or non-infectious) vectors that carry null or partial genes in the final drug product is classified as an impurity by the FDA. These impurities impair dosage accuracy and induce non-specific immunogenicity and variability in drug efficacy. These non-functional viral vectors in the drug product need to be elucidated following International Conference on Harmonization (ICH) guidelines for clinical manufacturing of the final drug product. This article showcases an ion-exchange chromatography (IEX) high-resolution method supporting ICH guidelines using commercially available AAV8 filled and empty capsids as reference standards. Our method successfully separated empty to full capsids with a resolution of 15 and sustained a linearity greater than 0.98 even under a wide range of empty or full viral particle concentrations (E+9 to E+13 vp/mL), which is an upgrade to other IEX capsid separation methods. The medium-throughput capacity and shorter sample processing time improve testing efficiency and save costs while delivering quality as value. The discussed method is a reliable and reproducible platform to precisely evaluate the presence of non-functional viral particles in AAV8 samples. Aligned with other orthogonal results, the method is a powerful tool to improve the quality of rAAV analytics.

Quality Control Method (UPLC-PDA) of Ajuga parviflora Benth. and Its Antiadipogenic Effect on Differentiated Preadipocytes

IntroductionAjuga parviflora is traditionally used for fever, diabetes, and digestive problems. Currently, Ultraperformance liquid chromatography-Photodiode array (UPLC-PDA) method to determine ajugasterone C, cyasterone, and vanillic acid in A. parviflora was focused to develop and validate a method for quality control perspective. Further, the evaluation of antiadipogenic and antidiabetic potential of A. parviflora was also targeted. MethodsUPLC-PDA method was developed and validated for targeted compounds as per International Council on Harmonisation guidelines. The validated method was used to determine marker compounds in A. parviflora extracts (Ethanol: EtOH, 50% EtOH, and water; leaves and roots). Further, UPLC-ELSD was used to determine free sugars in samples. Moreover, the antiadipogenic effect of A. parviflora extracts was examined on 3T3-L1 murine preadipocytes cell line. Cells were subjected to various dosages of leaves and root extracts, and the extent of lipid accumulation was evaluated. Furthermore, cells were treated with different extracts prior to hydrogen peroxide exposure, and then the effects of A. parviflora treatments on oxidative stress, cell survival, and insulin sensitisation were assessed. ResultsThe validated UPLC-PDA method was found reproducible to determine ajugasterone C, cyasterone, and vanillic acid. These compounds were found in all the samples. Biologically, leaves and roots extract of A. parviflora drastically suppressed adipogenesis by lowering intracellular lipid accumulation in dose-dependent manner. They improved insulin sensitivity by promoting glucose uptake and protected cellular health from oxidative damage by reducing reactive oxygen species generation and reversing apoptosis. ConclusionsFindings suggested that ethanol extract of leaves exhibited potent antiadipogenic properties and UPLC-PDA will be a reproducible method to assess quality of A. parviflora and its derived products.

Novel Green Chromatographic Approaches for Estimation of a Triple Common Cold Pharmaceutical Combination.

Nowadays, there is a strong interest in the scientific community in developing innovative methodologies within a green analytical chemistry framework. Herein, we introduce the first chromatographic approaches for the concurrent estimation of paracetamol (PAR), carbinoxamine (CRX), and pseudoephedrine (PSE) intended to relieve COVID-19 and common cold symptoms. The first method was thin layer chromatography (TLC) densitometry, which depends on the separation of the studied medications on TLC silica gel plates using ethyl acetate: methanol: ammonia (7.0: 3.0: 0.2, by volume) as the developing system, and were scanned at 208.0nm. The data were linear in the ranges of 1-25μg/band for PAR, 1-25μg/band for PSE and 0.1-5μg/band for CRX. The second method was reversed-phase high-performance liquid chromatography separation on a Kromasil C18 column using a mixture of 0.01M phosphate buffer containing 0.1% triethylamine (pH3.5) adjusted with orthophosphoric acid and ethanol at a flow rate of 1.0 mL/min in a gradient program. The separated peaks were detected at 215.0 nm over a concentration range of 10-250μg/mL for PAR, 5-35μg/mL for PSE, and 0.5-25μg/mL for CRX. Both approaches were validated according to International Conference on Harmonization (ICH) guidelines. Finally, the impact of these methods on the environment was evaluated by many tools.

Simultaneous Estimation of Monoterpenes (Eugenol, Eucalyptol and R-Limonene) by HPTLC Densitometric Method and Its Validation.

Plant-derived monoterpenes have various pharmacological applications, but the problem lies with their detection and estimation. Hence, it is crucial to develop a robust technique to overcome this problem. This work was aimed at developing a swift, accurate and reproducible technique for the simultaneous detection of three monoterpenes, namely, eugenol, eucalyptol (1,8- cineole), and R-limonene, using the high-performance thin-layer chromatography technique, as per International Council of Harmonization (ICH) guidelines. The best results were obtained in the eluent mixture prepared by using hexane: toluene: ethyl acetate (6:3:1, v/v/v), and silica gel-coated aluminum thin layer chromatography (TLC) plates 60F254 as a stationary phase that produced very sharp and well-resolved symmetrical peaks for eugenol, eucalyptol, and R-limonene at Rf values of 0.47 ± 0.03, 0.56 ± 0.03, and 0.71 ± 0.03, respectively. The linear range for eugenol, eucalyptol, and R-limonene was 1 to 15 ng/ spot (r2 = 0.9906), 100 to 600 ng/spot (r2 = 0.99625), 50 to 300 ng/spot (r2 = 0.9873), respectively. Furthermore, the limit of detection (LoD) and limit of quantitation (LoQ) values for eugenol were obtained at 0.0129 and 0.0391 ng/spot, followed by eucalyptol (0.82 and 2.48 ng/spot) and R-limonene (0.594 and 1.8 ng/spot), respectively. To our knowledge, we are the first to report a quick and reproducible high-performance thin-layer chromatography (HPTLC) technique for the simultaneous determination of eugenol, eucalyptol (1,8-cineole), and R-limonene. This method can further be used for the quantification of these secondary metabolites in plant extracts, enriched fractions, and pharmaceutical formulations.

Method Development and Validation for the Simultaneous Estimation of Lobeglitazone Sulphate and Glimepiride by HPLC Method.

A simple, precise, and accurate reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed for the simultaneous estimation of lobeglitazone sulfate and glimepiride in bulk and tablet dosage forms. The method involved selecting various chromatographic parameters. Specifically, a new method was developed using a 250 mm × 4.6 mm (HSS) reverse-phase C18 column with 5 µm particle size (Shim-pack C18, 250 × 4.6 mm; 5 µm). The mobile phase consisted of 40 volumes of phosphate buffer (pH 3) and 60 volumes of acetonitrile, with methanol as the diluent, running as an isocratic elution. The flow rate was set at 1.0 mL/min, and UV detection was performed at 254 nm. The injection volume was 2 µL, and the total runtime was 10 minutes. The recoveries for lobeglitazone sulfate were found to be in the range of 101% to 100.6%, while those for glimepiride were in the range of 101.5% to 100%. The method’s accuracy is evident from these results. The inter-day and intra-day precision of the new method were both below the maximum allowable limit (RSD% ≤ 2.0), as per International Council on Harmonisation (Q2 R1) guidelines. The method exhibited a linear response, with correlation coefficient (r2) values of 0.9972% for pioglitazone and 0.998 for glimepiride. The validation parameters, such as accuracy, precision, linearity, specificity, stability in the analytical solution and robustness, met the acceptance criteria. Hence, this method can be effectively used for the simultaneous estimation of lobeglitazone sulfate and glimepiride in both bulk and pharmaceutical dosage forms.

Identification and quantitative analysis of genotoxic impurities in rifampicin: Development and validation of a targeted LC-MS/MS method for 1-amino-4-methylpiperazine

Rifampicin, essential for long-term tuberculosis treatment, requires rigorous control of non-therapeutic impurities due to their potential adverse, including mutagenic effects. Reports on control strategies for genotoxic impurities in rifampicin have been limited. This study introduced an analytical method to identify potential genotoxic impurities from the synthesis of raw materials. The structure of the 25-deacetyl-23-acetyl-rifampicin genotoxic impurity was confirmed using nuclear magnetic resonance, high-resolution mass spectrometry (HRMS), and high-performance liquid chromatography (HPLC). An HPLC-HRMS method was established and validated for detecting another genotoxic impurity, 1-amino-4-methylpiperazine, adhering to the International Council on Harmonization guidelines, which include specificity, linearity, detection and quantification limits, accuracy, precision, and robustness. These developments improve the quality control strategy for genotoxic impurities in rifampicin, ensuring product safety.

Review on Analytical Method Validation for Trithioparamethoxy Phenylpropene & Chlorpheniramine Maleate in Pharmaceutical Dosage Form

Analytical method validation is a crucial step in ensuring the reliability and accuracy of analytical procedures employed for the determination of active pharmaceutical ingredients (APIs) in pharmaceutical dosage forms. This study focuses on the validation of analytical methods for the quantification of trithioparamethoxy phenylpropene and chlorpheniramine maleate in pharmaceutical dosage forms. The methods were developed using high- performance liquid chromatography (HPLC) or using ultra performance liquid chromatography (UPLC) with appropriate detection techniques. Parameters such as specificity, linearity, precision, accuracy, robustness, ruggedness, range, stability, LOD, LOQ and system suitability were evaluated according to International Conference on Harmonization (ICH) guidelines. The validated methods demonstrated excellent specificity, linearity over a wide concentration range, precise and accurate results, robustness against variations in method parameters, and suitable system suitability. The validated methods are suitable for routine quality control analysis of pharmaceutical formulations containing trithioparamethoxy phenylpropene and chlorpheniramine maleate, ensuring the reliability and consistency of drug products.

HPTLC quantification of garcinol in three endemic Garcinia species of Assam, estimation of secondary metabolites and evaluation of in vitro antioxidant activity

AbstractGarcinol, the main polyisoprenylated benzophenone present in Garcinia species. A simple, rapid, reliable high-performance thin-layer chromatography (HPTLC) technique has been developed for simultaneous detection and quantification of garcinol in three endemic Garcinia sp. of Assam, India. While G. mangostana and G. indica have garnered extensive recognition, these lesser-known species have not received proportionate level of scientific exploration, therefore has served as the subject of investigation. Chromatographic separation was achieved using pre-coated silica gel 60 F254 plates. The optimized mobile phase (Toluene-Ethyl acetate-Formic acid, 5:4:1V/V) at 276 nm produced well-defined and sharp peaks of garcinol, maintaining a constant RF value of 0.75. The regression equation demonstrated a linear relationship with a correlation coefficient of 0.9955. The method was validated in accordance with International Conference of Harmonization guidelines (ICH), encompassing assessments for precision, accuracy, repeatability and robustness, all of which yielded low percentage of relative standard deviation values, attesting to its excellent performance. The content of garcinol found in the extracts were in the range of 0.58–0.98% w/w. In secondary metabolite analysis, significant amount of phenols (26.06 ± 1.65–57.51 ± 2.62 gallic acid equivalent mg g−1), flavonoids (11.27 ± 1.06–21.09 ± 1.34 quercetin equivalent mg g−1) and ascorbic acid (3.56 ± 0.12–3.65 ± 0.11 mg/10 g) contents were detected in the extracts. Further, the extracts exhibited good anti-radical activity, which may be attributed to the presence of important secondary metabolites. Therefore, this research establishes the three endemic Garcinia sp. as promising source of garcinol. Additionally, the developed method can be applied for routine quality control analysis of herbal formulations containing garcinol.

Rapid microwave fabrication of highly luminescent nitrogen and phosphorous co-doped carbon quantum dots for the determination of glutathione in pharmaceutical supplements

A facile and sensitive nano-probe for spectrofluorometric glutathione (GSH) determination has been developed based on dual-doped nitrogen and phosphorus carbon quantum dots (NP@CQDs). The NP@CQDs were prepared, through a rapid, one-step microwave heating method in only 180 s with a high quantum yield (0.63) using ethylenediaminetetraacetic acid as carbon and nitrogen precursor and diammonium hydrogen phosphate as nitrogen and phosphorus dopant. The synthesised NP@CQDs had a maximum bluish fluorescence emission at 420 nm, after excitation at 360 nm. The luminescence of the prepared NP@CQDs was quenched via a static quenching mechanism by ferrous ions, while ferric ions did not affect the emission of NP@CQDs. GSH was mixed with ferric ions before adding NP@CQDs to exploit this observation. The attenuation in emission observed after adding NP@CQDs to GSH/ferric ions was directly related to the GSH concentration, as GSH worked to reduce the ferric ions present and produce ferrous ions. The proposed fluorometric method was validated in compliance with the International Council on Harmonization (ICH) guidelines. The proposed fluorescent nano-probe showed good linearity for GSH determination over a range of 0.5–10 µg/mL with % recoveries ranging between 99.50 and 101.86 %, and RSD less than 2 %. NP@CQDs were implemented for GSH determination in pharmaceutical supplementary capsules with respectable accuracy and precision. This approach is simple, reliable, accurate, specific, and it also does not require expensive chemicals or sophisticated equipment. This work opens up other uses of NP@CQDs in pharmaceutical and environmental analysis.

Development of cyclodextrin-electrokinetic chromatography-based strategies for the separation of ketorolac enantiomers

The development of analytical strategies enabling the chiral separation of ketorolac by electrokinetic chromatography is presented in this work. This anti-inflammatory drug is commercialised as racemic mixture but its physiological activity resides in the S-enantiomer. Different experimental conditions were investigated at acidic and neutral pH, including the use of cyclodextrins (CD) or amino acid-based ionic liquids (AAILs) ([TMA][L-Cit], [TMA][L-Arg], [TMA][L-Harg], [TBA][L-Cit], [TBA][L-Arg], and [TBA][L-Harg]) as the sole chiral selectors or the combination of a CD with AAILs or their cationic components (tetramethylammonium (TMA-OH) or tetrabutylammonium (TBA-OH)). The best conditions in terms of migration times and enantiomeric resolutions were obtained using 2 mM heptakis(2,3,6-tri-O-methyl)-β-CD (TM-β-CD) in 50 mM phosphate buffer at pH 7.0 or 2 mM TM-β-CD with 60 mM TMA-OH in 50 mM formate buffer at pH 3.0. The presence of TMA-OH in the separation medium affected considerably the electroosmotic flow (EOF) mobility which, in turn, significantly shortened the migration times for ketorolac enantiomers at pH 3.0 due to an inversion in the EOF. The multivariate optimization of the experimental conditions for the single system and for the combined system with TMA-OH enabled to obtain the separation of ketorolac enantiomers in less than 11 min with enantiomeric resolutions of 2.5 and 1.9, respectively. The single system was selected to evaluate its analytical characteristics in terms of limits of detection/quantification, accuracy, and precision, according to the International Council for Harmonization (ICH) guidelines, which resulted adequate to be applied to the analysis of pharmaceutical formulations.

Isolation, Identification, and Characterization of Forced Degradation Products of Bosentan by Using Advanced Analytical Techniques

ABSTRACTThe present study explains the degradation behavior of bosentan (BOS), active pharmaceutical ingredient (API) (BOS monohydrate), a Food and Drug Administration (FDA)–approved drug used for the treatment of chronic heart failure, subarachnoid hemorrhage, and Raynaud's syndrome pulmonary hypertension. The stress study was performed under various stress conditions such as acid hydrolysis, base hydrolysis, oxidation, thermal degradation, and photolysis as per International Council for Harmonization (ICH) guidelines and found three degradation products (DPs) under acid hydrolysis conditions (1 N HCl/4 h/60°C reflux conditions) (the net degradation of API ∼ 21.39%). The drug was found to be stable under the remaining conditions (thermal, photolytic, oxidative, and basic hydrolytic conditions). Mechanisms for forming the three acid DPs were also proposed and discussed. The DPs were initially detected by ultrahigh‐performance liquid chromatography–mass spectrometry analysis. These DPs were isolated by preparative HPLC and then characterized by high‐resolution mass spectrometry and nuclear magnetic resonance spectroscopy techniques. Based on the structural characterization study, all these DPs are new and not reported elsewhere in the literature to my knowledge. Many reports were found in the literature for the quantification of the drug in the APIs and formulation products. However, there is no report published yet for the identification and characterization of DPs of the BOS drug.